JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Search

Day One Biopharmaceuticals Inc

Fechado

SetorSaúde

7.05 -3.95

Visão Geral

Variação de preço das ações

24h

Atual

Mín

7

Máximo

7.26

Indicadores-chave

By Trading Economics

Rendimento

5.7M

-30M

Vendas

3.1M

34M

Margem de lucro

-89.424

Funcionários

182

EBITDA

5.2M

-35M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+220% upside

Dividendos

By Dow Jones

Próximos Ganhos

4 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

86M

768M

Abertura anterior

11

Fecho anterior

7.05

Sentimento de Notícias

By Acuity

50%

50%

154 / 373 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de out. de 2025, 23:28 UTC

Ações em Alta

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29 de out. de 2025, 23:07 UTC

Ganhos

Prudential PLC 3Q New Business Profit Up 13%

30 de out. de 2025, 00:00 UTC

Ganhos

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30 de out. de 2025, 00:00 UTC

Ganhos

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30 de out. de 2025, 00:00 UTC

Ganhos

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29 de out. de 2025, 23:46 UTC

Conversa de Mercado

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29 de out. de 2025, 23:40 UTC

Ganhos

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29 de out. de 2025, 23:38 UTC

Conversa de Mercado

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29 de out. de 2025, 23:25 UTC

Ganhos

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29 de out. de 2025, 22:51 UTC

Ganhos

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29 de out. de 2025, 22:45 UTC

Ganhos

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29 de out. de 2025, 22:41 UTC

Ganhos

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29 de out. de 2025, 22:41 UTC

Ganhos

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29 de out. de 2025, 22:09 UTC

Ganhos

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29 de out. de 2025, 22:08 UTC

Conversa de Mercado
Ganhos

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29 de out. de 2025, 21:58 UTC

Ganhos

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29 de out. de 2025, 21:58 UTC

Ganhos

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29 de out. de 2025, 21:57 UTC

Ganhos

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29 de out. de 2025, 21:54 UTC

Ganhos

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29 de out. de 2025, 21:46 UTC

Ganhos

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29 de out. de 2025, 21:43 UTC

Ganhos

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29 de out. de 2025, 21:43 UTC

Ganhos

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29 de out. de 2025, 21:42 UTC

Ganhos

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29 de out. de 2025, 21:42 UTC

Ganhos

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29 de out. de 2025, 21:41 UTC

Ganhos

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29 de out. de 2025, 21:41 UTC

Ganhos

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29 de out. de 2025, 21:41 UTC

Ganhos

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29 de out. de 2025, 21:41 UTC

Ganhos

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29 de out. de 2025, 21:40 UTC

Ganhos

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29 de out. de 2025, 21:39 UTC

Ganhos

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Comparação entre Pares

Variação de preço

Day One Biopharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

220% parte superior

Previsão para 12 meses

Média 24 USD  220%

Máximo 34 USD

Mínimo 16 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Day One Biopharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

9 ratings

8

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

6.26 / 7.47Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

154 / 373 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
help-icon Live chat